Top

Published in:

01-12-2018

Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study

Authors: Bhuma Krishnamachari, Mahin Rehman, Jason E. Cohn, Vivian Chan, Neil Modi, Ofri Leitner, Kelly Tangney, April O’Connor, William Blazey, Sharon Koehler, David Tegay

Published in: Journal of Cancer Education | Issue 6/2018

Abstract

The National Comprehensive Cancer Network (NCCN) guidelines are the gold standard in hereditary cancer risk assessment, screening, and treatment. A minority of physicians follow NCCN guidelines for BRCA1 or BRCA2 mutations. This study assesses the impact of an interventional educational program on HBOC in terms of knowledge. Physicians were sent an invite to join either an intervention survey (web-training offered prior to the knowledge survey) or control survey (web-training offered after the knowledge survey). Sixty-nine physicians in the intervention arm and 67 physicians in the control arm completed the survey. The interventional group regularly answered items correctly at a higher frequency than the control group. For example, 64.71% (n = 44) of physicians in the intervention group knew that multi-gene testing does not have to include only highly penetrant genes compared to 32.84% (n = 22) of the control group (p < 0.01). Similar results were seen with other specific survey items. The current study is important in that it shows web-based education to be a feasible and effective modality for training on hereditary breast cancer. This type of education may be incorporated into CME programs and can be used as a foundation for further studies as well.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30CrossRefPubMed

Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 222 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedPubMedCentral

Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329–1333CrossRefPubMed

Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367(9510):595–604CrossRefPubMed

Tai YC, Domchek S, Parmigiani G, Chen S (2007) Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99(23):1811–1814CrossRefPubMed

Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91(15):1310–1316

Tryggvadottir L, Vidarsdottir L, Thorgeirsson T et al (2007) Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99(12):929–935CrossRefPubMed

Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719CrossRefPubMedPubMedCentral

Pilarski R (2009) Cowden syndrome: a critical review of the clinical literature. J Genet Couns 18:13–27CrossRefPubMed

10.

Schneider K, Zelley K, Nichols KE, et al (2013) Li-Fraumeni Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1311/ Accessed 23 May 2017

11.

Brooks-Wilson AR, Kaurah P, Suriano G et al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41:508–517CrossRefPubMedPubMedCentral

12.

National Comprehensive Cancer Network (2017) Clinical practice guidelines in oncology, genetic/familial high-risk assessment: breast and ovarian version 2.. Available at: www.nccn.org . Accessed 12–29-16

13.

Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437CrossRefPubMed

14.

Daly MB, Axilbund JE, Buys S et al (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw 8(5):562–594CrossRef

15.

Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art Nat. Rev Clin Oncol 7:702–707CrossRef

16.

Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22(6):1055–1062CrossRefPubMed

17.

Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622CrossRefPubMed

18.

Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10(Suppl 1):S5–S9CrossRefPubMed

19.

Warner E, Causer PA (2005) MRI surveillance for hereditary breast-cancer risk. Lancet 365(9473):1747–1749CrossRefPubMed

20.

King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 286(18):2251–2256CrossRefPubMed

21.

Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340(2):77–84CrossRefPubMed

22.

Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615CrossRefPubMed

23.

Olivier RI, van Beurden M, Lubsen MA et al (2004) Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90(8):1492–1497CrossRefPubMedPubMedCentral

24.

Rutter JL, Wacholder S, Chetrit A et al (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95(14):1072–1078CrossRefPubMed

25.

Bellcross CA, Kolor K, Goddard KA et al (2011) Knowledge and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J of Prev Med 40(1):61–66CrossRef

26.

Epplein M, Koon KP, Ramsey SD et al (2005) Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute cancer centers. J Clin Oncol 23(21):4713–4718CrossRefPubMed

27.

Vig HS, Armstrong J, Egleston BL et al (2009) Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 13(6):735–741CrossRefPubMedPubMedCentral

28.

Moyer, Virginia A. on behalf of the U.S. preventive services task force* risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. preventive services task force recommendation statement, clinical guideline December 24, 2013

29.

Klitzman R, Chung W, Marder K, Shanmugham A, Chin LJ, Stark M, Leu CS, Appelbaum PS (2013) Attitudes and practices among internists concerning genetic testing. J Genet Couns 22:90–100CrossRefPubMed

30.

Sifri R, Myers R, Hyslop T, Turner B, Cocroft J, Rothermel T, Grana J, Schlackman N (2003) Use of cancer susceptibility testing among primary care physicians. Clin Genet 64:355–360CrossRefPubMed

31.

Dhar SU, Cooper HP, Wang T (2011) Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat 129(1):221–227CrossRefPubMedPubMedCentral

32.

Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN (2005) Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42(10):749–755CrossRefPubMedPubMedCentral

33.

Pal T, Cragun D, Lewis C, Doty A, Rodriguez M, Radford C et al (2013) A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers 17(5):367–375CrossRefPubMedPubMedCentral

34.

Carroll JC (2016 Oct) Primary care providers’ experiences with and perceptions of personalized genomic medicine. Can Fam Physician 62(10):e626–e635PubMedPubMedCentral

35.

Chan V, Blazey W, Tegay D, Harper B, Manning R, Koehler S, Laurent B, Cohn J, Lipka S, Jung M, Krishnamachari B Impact of academic affiliation and training on knowledge of hereditary colorectal cancer. Published online January 22, 2014

36.

Cohn J, Blazey W, Tegay D, Harper B, Manning R, Koehler S, Laurent B, Chan V, Jung M, Krishnamachari B (2014) Physician knowledge of ethnicity specific differences in BRCA genetic testing. Breast J 20(6):669–670CrossRefPubMed

37.

Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893–901CrossRefPubMed

38.

Cragun D, Scherr C, Camperlengo L, Vadaparampil ST, Pal T (2016) Evolution of hereditary breast cancer genetic services: are changes reflected in the knowledge and clinical practices of Florida providers? Genetic Testing and Molecular Biomarkers 20(10):569–578. doi:10.1089/gtmb.2016.0113 CrossRefPubMedPubMedCentral

39.

Young KJ, Kim JJ, Yeung G, Sit C, Tobe SW (2011) Physician preferences for accredited online continuing medical education. J Contin Educ Heal Prof 31(4):241–246CrossRef

40.

Paneque M, Turchetti D, Jackson L, Lunt P, Houwink E, Skirton H (2016) A systematic review of interventions to provide genetics education for primary care. BMC Fam Pract BMC Family Practice 17(1). doi:10.1186/s12875-016-0483-2

Title: Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study
Authors: Bhuma Krishnamachari
Mahin Rehman
Jason E. Cohn
Vivian Chan
Neil Modi
Ofri Leitner
Kelly Tangney
April O’Connor
William Blazey
Sharon Koehler
David Tegay
Publication date: 01-12-2018
Publisher: Springer US
Published in: Journal of Cancer Education / Issue 6/2018
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI: https://doi.org/10.1007/s13187-017-1233-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Raising Awareness for Lung Cancer Prevention and Healthy Lifestyles in Female Scholars from a Low-Income Area in Bogota, Colombia: Evaluation of a National Framework

Cervical Cancer Knowledge, Self-Efficacy, and Health Literacy Levels of Married Women

Reducing Liver Cancer Risk in African-Born Immigrants Through Culturally Targeted Hepatitis B Group Education Programs

The Impact of a Radiation Oncologist led Oncology Curriculum on Medical Student Knowledge

Stages of Change for Mammography Among Mexican Women and a Decisional Balance Comparison Across Countries

Using Comics to Promote Colorectal Cancer Screening in the Asian American and Pacific Islander Communities

Keynote webinar | Spotlight on antibody–drug conjugates in cancer